<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:identifier>https://scholia.toolforge.org/work/Q46758158</dc:identifier>
  <dc:identifier>http://www.wikidata.org/entity/Q46758158</dc:identifier>
  <dc:identifier>doi:10.1086/497126</dc:identifier>
  <dc:title>Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.</dc:title>
  <dc:creator>Patterson, Thomas F</dc:creator>
  <dc:creator>Boucher, Helen W</dc:creator>
  <dc:creator>Herbrecht, Raoul</dc:creator>
  <dc:creator>Denning, David W.</dc:creator>
  <dc:creator>Lortholary, Olivier</dc:creator>
  <dc:creator>Ribaud, Patricia</dc:creator>
  <dc:creator>Rubin, Robert H</dc:creator>
  <dc:creator>Wingard, John R</dc:creator>
  <dc:creator>DePauw, Ben</dc:creator>
  <dc:creator>Schlamm, Haran T</dc:creator>
  <dc:creator>Troke, Peter</dc:creator>
  <dc:creator>Bennett, John E</dc:creator>
  <dc:creator>Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG), European Organization</dc:creator>
  <dc:creator>Group, Pfizer Global Aspergillus Study</dc:creator>
  <dc:type>journal article</dc:type>
  <dc:date>2005-10-13</dc:date>
  <dc:language>en</dc:language>
  <dc:subject>theme:invasion impact</dc:subject>
  <dc:subject>theme:wikidata.org/entity/Q112148709</dc:subject>
  <dc:subject>aspergillosis</dc:subject>
  <dc:subject>invasive aspergillosis</dc:subject>
  <dc:subject>amphotericin B</dc:subject>
  <dc:subject>voriconazole</dc:subject>
  <dc:subject>invasion impact</dc:subject>
  <dc:publisher>Oxford University Press (OUP)</dc:publisher>
</oai_dc:dc>